

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT TRIAL AND APPEAL BOARD

ADAMIS PHARMACEUTICALS CORPORATION
Petitioner

v.

BELCHER PHARMACEUTICALS, LLC
Patent Owner

CASE: IPR2019-01021
U.S. PATENT NO. 9,283,197

PETITION FOR *INTER PARTES* REVIEW

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
PO Box 1450
Alexandria, Virginia 22313-1450

Table of Contents

	<u>Page</u>
I. INTRODUCTION	1
II. OVERVIEW OF THE TECHNOLOGY	2
A. Epinephrine Compound	2
B. Epinephrine Injection Formulations	3
C. Racemization and Oxidation Processes	5
D. Adrenalone and Other Impurities	7
III. U.S. PATENT NO. 9,283,197	8
A. ‘197 Patent Overview	8
B. Prosecution History of the ‘197 Patent	9
IV. GROUNDS FOR STANDING (37 C.F.R. §42.104(a))	11
V. PAYMENT OF FEES (37 C.F.R. §§42.15 AND 42.103)	11
VI. MANDATORY NOTICES (37 C.F.R. §42.8)	11
A. Real Parties-In-Interest	11
B. Related Matters	11
C. Lead and Backup Counsel and Service	12
D. The Petition Relies on Previously Unapplied Prior Art	12
VII. PERSON OF ORDINARY SKILL IN THE ART	14
VIII. CLAIM CONSTRUCTION	15
IX. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFOR (37 C.F.R. §§42.22(a) AND 42.104(b))	17

A. Ground 1: Claim 6 is Unpatentable Under 35 U.S.C. §102 as Anticipated by <i>Stepensky</i>	18
1. Overview of the Prior Art of Ground 1	18
a. <i>Stepensky</i>	18
2. Claim 6	21
a. Preamble	21
b. <i>said liquid pharmaceutical formulation having a pH between 2.8 and 3.3</i>	21
c. <i>said injectable liquid pharmaceutical formulation compounded in an aqueous solution as 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent</i>	22
d. <i>said liquid pharmaceutical formulation including no more than about 6% d-epinephrine and no more than about 0.5% adrenalone at release</i>	22
e. <i>said liquid pharmaceutical formulation including no more than about 12% d-epinephrine and no more than about 0.5% adrenalone over a shelf-life of at least 12 months</i>	24
B. Ground 2: The Challenged Claims are Unpatentable Under 35 U.S.C. §103 Over <i>Stepensky</i> in view of <i>USP</i>	25
1. Overview of the Prior Art of Ground 2	25
a. <i>Stepensky</i>	25
b. <i>USP</i>	25
c. The Combination of <i>Stepensky</i> and <i>USP</i>	26
2. Claim 6	27
a. Preamble	27

b.	<i>said liquid pharmaceutical formulation having a pH between 2.8 and 3.3</i>	28
c.	<i>said injectable liquid pharmaceutical formulation compounded in an aqueous solution as 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent</i>	29
d.	<i>said liquid pharmaceutical formulation including no more than about 6% d-epinephrine and no more than about 0.5% adrenalone at release</i>	30
e.	<i>said liquid pharmaceutical formulation including no more than about 12% d-epinephrine and no more than about 0.5% adrenalone over a shelf-life of at least 12 months</i>	30
3.	Claim 7	31
a.	<i>The said injectable liquid pharmaceutical formulation of claim 6 further having a concentration of 1 mg per mL l-epinephrine</i>	31
C.	Ground 3: The Challenged Claims are Unpatentable Under 35 U.S.C. §103 Over <i>Stepensky</i> in View of <i>Gupta</i>	32
1.	Overview of the Prior Art of Ground 3	32
a.	<i>Gupta</i>	32
b.	The Combination of <i>Stepensky</i> and <i>Gupta</i>	35
2.	Claim 6	36
a.	<i>Preamble</i>	36
b.	<i>said liquid pharmaceutical formulation having a pH between 2.8 and 3.3</i>	37
c.	<i>said injectable liquid pharmaceutical formulation compounded in an aqueous solution as 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent</i>	37

d.	<i>said liquid pharmaceutical formulation including no more than about 6% d-epinephrine and no more than about 0.5% adrenalone at release</i>	38
e.	<i>said liquid pharmaceutical formulation including no more than about 12% d-epinephrine and no more than about 0.5% adrenalone over a shelf-life of at least 12 months</i>	39
3.	Claim 7	40
a.	<i>The said injectable liquid pharmaceutical formulation of claim 6 further having a concentration of 1 mg per mL l-epinephrine</i>	40
D.	Ground 4: the Challenged Claims are Unpatentable Under 35 U.S.C. §103 Over <i>Bruss</i> in View of <i>USP</i> and <i>Fyllingen</i>	40
1.	Overview of the Prior Art of Ground 4	41
a.	<i>Bruss</i>	41
b.	<i>USP</i>	42
c.	<i>Fyllingen</i>	42
d.	The Combination of <i>Bruss</i> in view of <i>USP</i> and <i>Fyllingen</i>	43
2.	Claim 6	44
a.	<i>Preamble</i>	44
b.	<i>said liquid pharmaceutical formulation having a pH between 2.8 and 3.3</i>	45
c.	<i>said injectable liquid pharmaceutical formulation compounded in an aqueous solution as 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent</i>	46
d.	<i>said liquid pharmaceutical formulation including no more than about 6% d-epinephrine and no more than about 0.5% adrenalone at release</i>	47

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.